


2nd MIDDLE EAST MASTER CLASS IN HEMATOLOGY



January 10th - 12th, 2025 | Raffles Hotel, Dubai - UAE

www.memachematology.com

WELCOME LETTER



Dear Friends & Colleagues,

Following the resounding success of MEMAC 2024, we are excited to announce the 2nd **Middle East Master Class in Hematology (MEMAC) 2025**. This event, held in collaboration with the International Academy for Clinical Hematology (IACH), will take place from **January 10th to 12th, 2025**, at **the Raffles Hotel in Dubai, UAE**.

The field of hematology continues to be highly dynamic, with groundbreaking pathophysiological findings and innovative therapies constantly emerging. The development of new drugs, such as targeted medicines and immunotherapies, underscores the necessity for sharing expertise to enhance patient care and treatment quality through professional competence and excellence.

Building on this foundation, the primary goal of the MEMAC course is to empower local and regional hematologists with the latest knowledge on managing hematological malignancies. The program will feature the most effective strategies for treating acute and chronic leukemia, lymphomas, and multiple myeloma, providing you with practical tools to enhance your patient care and treatment quality.

We are thrilled to host this eagerly awaited event once again and are committed to exceeding all expectations. For updates and further information, please visit www.memachematology.com

We are eagerly anticipating another successful and enlightening event that will further enrich your understanding of hematology!

Warm regards,



Ali Bazarbachi, MD, PhD
Congress Co-chair



Mohamad Mohty, MD, PhD
Congress Co-chair


EBAH-CME CREDIT POINTS




The program of the 2nd **Middle East Master Class in Hematology (MEMAC) 2025** - from **January 10th to 12th, 2025**, at **the Raffles Hotel in Dubai, UAE**, has been reviewed and approved for CME accreditation by the European Board of Accreditation in Hematology (EBAH) CME Unit. The EBAH-CME Unit has approved this educational activity for a maximum number of CME credits. Each physician should only claim credits for time that they actually spent in the educational activity. We are pleased to inform you that the 2025 MEMAC has been awarded:



10 EBAH-CME Credit Points



09:00 - 09:30	Welcome Coffee & Registration	
09:30 - 10:40	Session 1: State-of-the-Art Diagnosis & Therapy in Myeloid Malignancies Chairs: Asma Alolama, MD - Colette Hanna, MD - Mohamad Azzam Ziadeh, MD	
09:30 - 09:50	MDS	 Amer Zeidan, MD
09:50 - 10:10	Myelofibrosis	 Ibrahim Yakoub-Agha, MD
10:10 - 10:30	Updates in Eosinophilia	 Hanan Hamed, MD
10:30 - 10:40	 Q&A	
10:40 - 11:10	Industry Symposium Beigene BTK Inhibitors in CLL: Redefining Standards of Care and Overcoming Challenges	 Ghazi Alotaibi, MD
11:10 - 11:25	 Coffee Break	



11:25 - 12:15


● **Session 2: State-of-the-Art Diagnosis & Therapy in ALL**
Chair: Ahmad Alhuraiji, MD







11:25 - 11:45	ALL (Ph-)	● Elias Jabbour, MD
11:45 - 12:05	ALL (Ph+)	● Robin Foà, MD
12:05 - 12:15	🗣️ Q&A	


12:15 - 13:45

Prayers & Lunch Break

13:45 - 15:15	Industry Symposium Sanofi <i>Chairs: Mohamad Mohty, MD - Mahmoud Marashi, MD</i>	
13:45 - 14:05	● Shifting the Needle: New Approaches in Ti NDMMs	● Mohamad Mohty, MD
14:05 - 14:20	● Panel Discussion <i>Panelists: Mohamad Mohty, MD - Mahmoud Marashi, MD - Ayman Alhejazi, MD - Ghazi Alotabi, MD</i>	
14:20 - 14:35	● Weighing Up the Options: Selecting Treatment in RRMM	● Ayman Hejazi, MD
14:35 - 14:45	● Clinical Case Discussion	● Omar AbdelJaleel, MD
14:45 - 15:00	● Panel Discussion <i>Panelists: Mohamad Mohty, MD - Amar Lal, MD - Ibrahim Almotabi, MD - Majed Alahmadi, MD</i>	
15:00 - 15:10	● Navigating the Path: Optimal Treatment Sequencing from First-Line Therapy in MM	● Mohamad Mohty, MD
15:10 - 15:15	● Panel Discussion <i>Panelists: Ayman Alhejazi, MD - Ghazi Alotabi, MD - Mahmoud Marashi, MD</i>	



15:15 - 15:45	<div><div>●</div><div><div>Industry Symposium Takeda</div><div>Cancer Related Secondary Immunodeficiencies: Middle East Consensus</div></div></div>	<div><div>●</div><div><div></div><div>Faraz Khan, MD</div></div></div>
15:45 - 16:35	<div><div>●</div><div><div>Session 3: State-of-the-Art Diagnosis and Therapy in Chronic Leukemias</div><div>Chair: Tareq A.Alobaidy, MD</div></div></div>	
15:45 - 16:05	<div><div>●</div><div>Mastocytosis</div></div>	<div><div>●</div><div><div></div><div>Olivier Hermine, MD</div></div></div>
16:05 - 16:25	<div><div>●</div><div>CML</div></div>	<div><div>●</div><div><div></div><div>Giuseppe Saglio, MD</div></div></div>
16:25 - 16:35	<div><div>●</div><div><div> Q&A</div></div></div>	
16:35 - 17:10	<div><div>●</div><div><div>Industry Symposium Amgen</div><div>Chair: Faraz Khan, MD</div><div>Updates in the Management of RRMM</div></div></div>	<div><div>●</div><div><div></div><div>Hasan Al-Yaseen, MD</div></div></div>
17:10 - 17:25	<div><div>●</div><div><div> Coffee Break</div></div></div>	



17:25 - 18:25

Session 4: Plenary Lecture

Chairs: Shahrukh Hashmi, MD - Bassim Albeirouti, MD - Zahira Fahed, MD

17:25 - 17:45

CLL

🇺🇸 Mohamed Kharfan-Dabaja, MD

17:45 - 18:15

APL

🇫🇷 Hugues de Thé, MD

18:15 - 18:25

🕒 Q&A

18:25 - 19:15

Session 5: Opening Lecture

Chairs: Khalid Halahleh, MD - Mahmoud Marashi, MD

18:25 - 19:10

Targeted Therapies in AML

🇺🇸 Hagop Kantarjian, MD

19:10 - 19:15

🕒 Q&A

SATURDAY JANUARY 11



09:00 - 09:15

Registration

09:15 - 10:05

Session 6: State-of-the-Art Diagnosis & Therapy in Bone Marrow Failures & Precursor Conditions

Chairs: Jean El Cheikh, MD - Kayane Mheidly, MD

09:15 - 09:35

MGUS + SMM

 Meletios Athanasios Dimopoulos, MD

09:35 - 09:55

Bone Marrow Failures

 Syed Osman Ahmed, MD

09:55 - 10:05

 Q&A

10:05 - 10:45

Industry Symposium Janssen

Chair: Mohamed Mohty, MD

Optimizing Treatment Strategies: Multiple Myeloma
Management Consensus in the Gulf Region

 **Mahmoud Marashi, MD**

 **Ahmad Alhuraiji, MD**

10:45 - 11:00

 **Coffee Break**

SATURDAY JANUARY 11



11:00 - 11:50

Session 7: State-of-the-Art Diagnosis & Therapy in Lymphoma

Chairs: Reyad Dada, MD - Muna Altarshi, MD - Rasha Ghanema, MD

11:00 - 11:20

T-Cell Lymphoma

 Gandhi Damaj, MD

11:20 - 11:40

Hodgkin Lymphoma

 Anna Sureda, MD

11:40 - 11:50

 Q&A

11:50 - 12:20

Industry Symposium Takeda

Chair: Ali Bazarbachi, MD

Improving Survival Outcomes in Advanced Stage cHL

 **Anna Sureda, MD**

12:20 - 12:50

Industry Symposium Sandoz

Rixathon in Hematology: What is New?

 **Jörgen Kristensen, MD**

12:50 - 13:45

 **Lunch Break**

13:45 - 14:15

Industry Symposium Astellas

Chair: Emmanouil Nikolousis, MD

Navigating Treatment Options for UNFIT Patients with RR AML

 **Kayane Mheidly, MD**



SATURDAY JANUARY 11

14:15 - 15:25

● **Session 8: State-of-the-Art Diagnosis & Therapy in Multiple Myeloma**

Chairs: Shabeeha Rana, MD - Ghada ElGohary, MD - Nour Moukalled, MD

14:15 - 14:35

Young and Fit Patients

●  Jean Luc Harousseau, MD

14:35 - 14:55

Elderly and Frail Patients

●  Thierry Facon, MD

14:55 - 15:15

Relapsed / Refractory Myeloma

●  Mohamad Mohty, MD

15:15 - 15:25

🔗 Q&A

15:25 - 16:05

● **Industry Symposium Janssen**

Chair: Alaa Fadhil Alwan , MD

The Evolving Treatment Paradigms in Triple Class Refractory MM Patients

●  **Ali Bazarbachi, MD**

16:05 - 16:20

☕ **Coffee Break**

16:20 - 16:55

● **Session 9: Plenary Lecture**

Chairs: Arif Alam, MD - Iman Abou Dalle, MD

16:20 - 16:50

The Revolution of Bispecific Antibodies

●  Hermann Einsele, MD

16:50 - 16:55

🔗 Q&A

SUNDAY

JANUARY 12



09:30 - 10:00

Registration

10:00 - 10:55

Session 10: How I Use MRD in Blood Cancers

Chairs: Magdy Elbordiny, MD - Ibrahim Abu Gheida, MD

10:00 - 10:20

The Case for Myeloma

•  Claudio Cerchione, MD

10:20 - 10:40

The Case for ALL

•  Eolia Brissot, MD

10:40 - 10:55

• Q&A

10:55 - 11:20

 **Coffee Break**



SUNDAY

JANUARY 12

11:20 - 12:15

Session 11: Novel Therapies in Hematology

Chairs: Ali Bazarbachi, MD - Mohamed Mohty, MD

11:20 - 11:40

CAR T-Cells in Lymphoma

•  Anna Ossami Saidy, MD

11:40 - 12:00

Microbiota

•  Florent Malard, MD

12:00 - 12:15

 Q&A

12:15 - 12:30

Closing Remarks: Ali Bazarbachi, MD - Mohamed Mohty, MD

12:30

 **Lunch Break**

sanofi

Johnson & Johnson
Innovative Medicine



AMGEN[®]



SANDOZ

Biologix^{FZCO}

